This volume documents the progress that has been made in the treatment of lung cancer, examining in detail the applicability and use of the various therapeutic modalities. Emphasis is placed on the benefits of a multimodality approach to lung cancer, and the editors have sought to achieve a balance between the perspectives offered by US and European authors. The comprehensive coverage of the subject and the expertise of the authors ensure that the volume will be of widest interest.

Klappentext

This volume provides a comprehensive account of the progress that has been made in the treatment of lung cancer. The various therapeutic approaches are documented and appraised, with particular emphasis being placed on the benefits of a multimodality strategy. A balance is sought between US and European perspectives, and all of the authors are recognized experts in the field.

Inhalt

1 Prognostic Factors: From Clinical Parameters to New Biological Markers J.B. Sorensen and K. Osterlind 2 Radiological Evaluation of Intrathoracic Extension and Resectability of Non-Small Cell Lung Cancer J.A. Hanson and P. Armstrong 3 Positron Emission Tomography: A New Toolin Diagnosing Staging and Treatment of Lung Cancer C. Schiepers 4 Exclusive Surgery for Stage III Disease: Is it Still Ethical P. Rocmans 5 Induction Chemotherapy With or Without Radiotherapy Followed by Surgery in Non-Small Cell Lung Cancer K.S. Albain 6 Adjuvant Treatment in Non-Small Cell Cancer S.S. Leong, C.M.S. Rocha Lima, and M.R. Green 7 Induction or Concurrent Chemotherapy and Radiotherapy for Locally Advanced Non-Small Cell Lunger Cancer R. Komaki and J.D. Cox 8 Exclusive Radiotherapy for NSC Lung Cancer H.-P. Heilmann, F. Wuerschmidt, and H. Buenemann 9 3D Conformal Radiotherapy in Treatment of Bronchogenic Carcinoma B. Emami 10 Endoluminal Brachytherapy: A Curative Modality? E. Lartigau, H. Marsiglia, and P. Baldeyrou 11 Integration of Radiotherapy and Chemotherapy for Small Cell Lung Cancer H. Wagner 12 The Role of PCI: Benefits and Late Effects A. Gregor and A. Cull 13 Fractionation as a Biological Dose Modifier M.I. Saunders 14 Biochemical and Biological Dose Modifyers for Irradiation of Lunger Cancers R.O. Mirimanoff 15 Intraoperative Radiotherapy for Lung Cancer F.A. Calvo, J.J. Aristu, M. Moreno, M. Santos, and S.A. Fisher 16 Should all Stage IV be Treated Palliatively? F. Cappuzzo, A. Zappala, and T. Le Chevalier Thierry 17 Intensive Therapy of Small Cell Lunger Cancer: A Review of Recently Published Data J. Klastersky and D. Derriendt 18 Best Supportive Care or Chemotherapy for Stage IV Non-Small Cell Lung Cancer J.P. Sculier, T. Berghmans, C. Castaigne, Y. Lalami, S. Luce, C. Sotiriou, P. Vermylen,, and M. Paesans 19 Do we have the Real Tool to Evaluate Toxicity? The Lent Soma Approach F. Mornex, J.J. Pavy, and J. Denekamp 20 The Issue of Treatment Indication and Clinical Target Volume P. Van Houtte, D. Ball, S. Danhier, and P. Scalliet 21 Radiotherapy and the Challenge of Palliation F. MacBeth and N. Thatcher 22 New Drugs in Cell Lung Cancer J.E. Dancey and F.A. Shepherd 23 Supportive Treatment in the Management of Lunger Cancer L. Crino Subject Index List of Contributors